Advertisement Pharmaceutical Business review - Page 372 of 5289 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 7, 2026

FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer

The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca’s Etcamah (camizestrant), used with a cyclin-dependent kinase (CDK) 4/6 inhibitor (abemaciclib, palbociclib or ribociclib), for breast cancer.

The combo is approved for adults with locally advanced or metastatic breast cancer. Credit: NMK-Studio / Shutterstock.com.